Stockreport

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF – U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne mu [Read more]